奥曲肽联合多巴胺治疗肝肾综合征疗效观察  

The therapeutic effects of octretide combined with dopamine on hepatorenal syndrome

作　　者：姚杰[1] 王志刚[1] 

机构地区：[1]解放军161医院肿瘤科,武汉430010

出　　处：《临床肾脏病杂志》2010年第5期214-216,共3页Journal Of Clinical Nephrology

摘　　要：目的观察奥曲肽联合多巴胺对肝癌晚期肝肾综合征（HRS）的疗效。方法将32例肝癌晚期HRS患者随机分成对照组和治疗组，分别采用多巴胺单独和联合奥曲肽进行治疗，比较2组治疗前、后尿量和肾功能。结果与治疗前相比，2组患者治疗后尿量均增加（P〈0．05），治疗组治疗后血肌酐、尿素氮降低（P〈0．05），而对照组无差异（P〉0．05）；治疗后，治疗组血肌酐、尿素氮较对照组降低（P〈0．05）；治疗组总有效率为77．8％，对照组总有效率为35．7％，治疗组疗效优于对照组（P〈0．05）。结论奥曲肽联合多巴胺治疗能使患者HRS逆转，对改善HRS患者预后有积极的作用。Objective To investigate and analysis the therapeutic effects of octretide combined with dopamine on hepatorenal syndrome（HRS） in late stage hepatocarcinoma. Methods 32 cases with late stage hepatocarcinoma and HRS were randomly divided into two groups： dopamine alone group （control group）and dopamine combined with octretide group（treatment group）. The kidney function and volume of urine output were observed. Results The volume of urine output in two groups were increased significantly after treatment （P〈0.05）, the serum creatinine and blood urea nitrogen level in treatment group were remarkablely decreased （P〈0. 05）, while in the control group were not apparently decreased （P〉0. 05）. And also the serum creatinine and blood urea nitrogen level in treatment group were remarkablely decreased with in control group after treatment （P〈0.05）. The total effective rate in treatment group was 77.8% ,the total effective rate in control group was 35.7% ,the therapeutic effects of treatment group was better than of the control group （P〈0. 05）. Conclusion Octretide combined with doparnine might reverse HRS and improve prognosis of late stage hepatocarcinoma patients with HRS.

关 键 词：肝肾综合征 多巴胺 生长抑素 

分 类 号：R575[医药卫生—消化系统]